CASI Pharmaceuticals, Inc. (PNK: CASIF) AI-Powered Stock Analysis
See how CASI Pharmaceuticals, Inc. scores across key metrics like financial growth, valuation, and market position on the PNK, using AI-driven evaluation.
CASIF●PNK
HealthcareBiotechnology
$0.13
$0.00(0.00%)
U.S. Market opens in 19h 41m
CASI Pharmaceuticals, Inc. (PNK: CASIF) AI-Powered Stock Analysis
See how CASI Pharmaceuticals, Inc. scores across key metrics like financial growth, valuation, and market position on the PNK, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerCASI Pharmaceuticals, Inc. (PNK: CASIF) Stock Overall Grade
CASI Pharmaceuticals, Inc.'s grade for its PNK listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to CASI Pharmaceuticals, Inc.'s overall PNK stock rating.
Forecast
C+Score
53/100Financial Growth
B+Score
70/100Fundamental Growth
BScore
69/100Key Ratios
B+Score
70/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
50/100CASI Pharmaceuticals, Inc. (PNK: CASIF) AI-Powered Stock Analysis
On the PNK, CASIF demonstrates Good performance with an overall Forecast Score of 53/100 (C+), reflecting weak confidence in its potential. Financial Growth (70/100, B+) and Fundamental Growth (69/100, B) highlight its stability, while Key Ratios (70/100, B+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the PNK-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(PNK: CASIF) Component Analysis Explained
Understand the key factors behind each CASI Pharmaceuticals, Inc. (PNK: CASIF) stock grade, including financials, comparisons, and forecasts.